Azusa

Researchers are studying women with dysmenorrhea, a condition involving painful periods, to see if they have a stronger musculoskeletal and autonomic nervous system response to painful internal stimuli compared to women without this pain. The study also aims to explore how interoceptive awareness, or the ability to sense internal body signals, might affect this relationship. This investigation seeks to better understand pain perception and related body changes in women with this condition. The study involves two groups women with moderate to severe menstrual pain and age-matched controls with mild or no pain. Participants will attend two sessions one for information and preparation, including tracking their menstrual cycle and heart rate variability HRV daily for 30 days, and a lab session where they will receive a controlled visceral pain stimulus. During the lab visit, hip mobility and muscle strength will be measured before and after the pain stimulus, and HRV will be recorded throughout. Participants will fill out questionnaires, perform daily HRV measurements with a phone app, and attend a lab session where detailed physical and physiological assessments occur. The study will measure changes in hip range of motion, muscle strength, and heart rate variability immediately after the pain stimulus. It will also assess interoceptive awareness during testing. The total participation includes daily monitoring for about a month and a single lab visit, with safety and comfort maintained throughout.

Researchers are evaluating the efficacy and safety of DFL24498, a topical ophthalmic solution, compared with a vehicle solution in adults with dry eye disease. This Phase 2, randomized, double-masked, vehicle-controlled study will enroll about 417 participants aged 18 years or older across multiple centers in the US. The study duration is up to 16 weeks and consists of three distinct periods. Participants are assigned to receive either DFL24498 or the vehicle solution, both administered as one drop in each eye four times daily for 12 weeks. The study includes a vehicle-controlled parallel group design. After the 12-week treatment period, there is a 2-week follow-up phase to monitor safety and outcomes. Throughout the study, participants will undergo assessments including corneal fluorescein staining, ocular dryness symptom evaluation using the SANDE questionnaire, tear production measurement with the Schirmer I test, and conjunctival fluorescein staining. Researchers will also track treatment-emergent adverse events. The primary outcome focuses on the change in corneal staining from baseline to week 12, with safety monitored during and after treatment.